MedPath

安徽省先锋制药有限公司

Ownership
-
Established
2004-01-14
Employees
-
Market Cap
-
Website
http://www.xfcn.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

103

NMPA:103

Drug Approvals

Ceftizoxime Sodium for Injection

Product Name
注射用头孢唑肟钠
Approval Number
国药准字H20254072
Approval Date
May 13, 2025
NMPA

Ceftizoxime Sodium for Injection

Product Name
注射用头孢唑肟钠
Approval Number
国药准字H20254071
Approval Date
May 13, 2025
NMPA

Orlistat Capsules

Product Name
奥利司他胶囊
Approval Number
国药准字H20253673
Approval Date
Mar 25, 2025
NMPA

Orlistat Capsules

Product Name
奥利司他胶囊
Approval Number
国药准字H20253674
Approval Date
Mar 25, 2025
NMPA

Ertapenem Sodium for Injection

Product Name
注射用厄他培南钠
Approval Number
国药准字H20253345
Approval Date
Feb 8, 2025
NMPA

Biapenem for Injection

Product Name
注射用比阿培南
Approval Number
国药准字H20253173
Approval Date
Jan 14, 2025
NMPA

Glucosamine Sulfate Capsules

Product Name
硫酸氨基葡萄糖胶囊
Approval Number
国药准字H20249696
Approval Date
Dec 6, 2024
NMPA

Fluvoxamine Maleate Tablets

Product Name
马来酸氟伏沙明片
Approval Number
国药准字H20249543
Approval Date
Dec 1, 2024
NMPA

Polyethylene Glycol Electrolytes Powder (III)

Product Name
复方聚乙二醇电解质散(Ⅲ)
Approval Number
国药准字H20249673
Approval Date
Dec 1, 2024
NMPA

Fluvoxamine Maleate Tablets

Product Name
马来酸氟伏沙明片
Approval Number
国药准字H20249544
Approval Date
Dec 1, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 11
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.